The scientific advisor for Operation Warp Speed floated the idea today of cutting the Moderna doses in half, from two 100 microgram doses to two 50 microgram doses. 1/n nytimes.com/live/2021/01/0…
It appears that he’s relying on Phase 2 trial results, in which 200 people under 55 got 50 micrograms of Moderna and had comparable antibody responses to people who got 100 micrograms. 2/n
That assumes that antibody levels are a correlate of protection. There’s data from monkeys that this *might* be true, but nothing yet from people that I’ve seen. nytimes.com/2020/12/04/hea… 3/n
And there’s the 200 people who got 50 micrograms in the Phase 2 study. After running a 30,000-person Phase 3 trial, that’s a pretty small hook to hang one’s hat on.
Moderna didn’t reply to @KatherineJWu right away, so we’ll see what they say. /end
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I've been working with @13pt on a series of brief visual explainers for how different leading vaccines work. Here's a thread of links, starting with Novavax nytimes.com/interactive/20…
Vaccines are essential to fighting back the coronavirus. If one gets authorized in the next few months, what will that mean for 2021? One expert put it this way to me: get ready for “complexity and chaos and confusion.” Here’s my preview for @nytimesnytimes.com/2020/10/12/hea… 1/9
The first vaccine may be mediocre. A superior one may still be in development. But the first vaccine’s authorization could immediately affect all the other vaccines still in Phase 3 trials—and could seriously hamper vaccines in earlier stages of research. 2/9
To have enough doses for the whole country by the spring, the US government is counting on several vaccines getting emergency authorization. But guidelines for choosing between them could be very challenging, because their trials are all running separately. 3/9
Thread: You may have heard of #COVID-19 vaccines in advanced clinical trials—Moderna, Pfizer, AstraZeneca and the like. But there’s a huge second wave of vaccines on their way. nytimes.com/2020/08/27/hea… [1/7]
I recently decided to take a look at this second wave. I reached out to all the companies and universities I could find that have announced preclinical studies since the beginning of the pandemic. [2/7]
I was able to confirm that 88 vaccines are still being actively investigated at the preclinical stage. Of these, 67 are on track to go into clinical trials in humans between now and the end of 2021. [3/7]
First up: Oxford scientists publish their first clinical trial paper on their chimp adenovirus vaccine, to be made by Astra Zeneca. Phase I/II trial indicates it’s safe (lots of mild side effects), produces some antibodies, some interferon. 2/9
CanSinoBio has its own paper out in the Lancet, demonstrating an immune response to a vaccine based on another adenovirus, Ad5 3/9
A lot of us science writers realized at some point a while back that we were going to be full-time #covid19 writers for a while. Maybe a very long while. Still, this past week felt especially bizarre, story-wise. An ICYMI thread 1/8
Working with @13pt on these visual explainers been a real privilege. Images can communicate some concepts so much better than words. Here’s a piece we did earlier on the SARS-CoV-2 genome: nytimes.com/interactive/20… and one on how the virus invades: nytimes.com/interactive/20… 3/8